Advanced Medical Optics, Inc. (AMO) [NYSE:EYE],
a global leader in ophthalmic surgical devices and eye care products,
today announced that it plans to begin shipping a multipurpose solution
in the U.S. in the first half of August and expects the product will be
widely available to consumers in the U.S. by early September. The
company had previously projected the product would not be available
until late September.
The new product will focus on comfort and disinfection efficacy,
incorporating the importance of proper handling and care of contact
lenses, per guidelines set forth by professional eye care associations
including the American Academy of Optometry (AAO), American Optometric
Association (AOA), the American Academy of Ophthalmology (AAO) and the
American Society of Cataract and Refractive Surgery (ASCRS).
AMO plans to ship to other global regions in a phased-in approach
throughout the fall. This timeline does not impact previous guidance
provided on June 26.
AMO expects to provide more information on its launch plans during the
second quarter earnings conference call set for August 2.
About Advanced Medical Optics (AMO)
AMO develops advanced, life-improving vision technologies for people of
all ages. Products in the cataract/implant line include intraocular
lenses (IOLs), phacoemulsification systems, viscoelastics, and related
products used in ocular surgery. AMO owns or has the rights to such
product brands as ReZoom®,
Tecnis®, Clariflex®,
Sensar®, and Verisyse®
IOLs, Sovereign®,
Sovereign® Compact
and WhiteStar Signature?
phacoemulsification systems with WhiteStar®
technology, Healon®
viscoelastics, and the Baerveldt®
glaucoma shunt. Products in the laser vision correction line include
wavefront diagnostic devices, femtosecond lasers and associated patient
interface devices, and excimer laser vision correction systems and
treatment cards. AMO brands in the laser vision correction business
include Star S4 IR®,
WaveScan Wavefront®,
CustomVue®,
IntraLase®
FS, IntraLase Method?
and IntraLasik®.
Products in the contact lens care line include disinfecting solutions,
enzymatic cleaners and lens rewetting drops. Among the eye care product
brands the company possesses are COMPLETE®,
COMPLETE®
Blink-N-Clean®,
Consept®F, Consept®
1 Step, Oxysept® 1
Step, UltraCare®,
Ultrazyme®, Total
Care? and blink?
branded products. AMO is based in Santa Ana, California, and employs
approximately 4,200 worldwide. The company has operations in 24
countries and markets products in approximately 60 countries. For more
information, visit the company's Website at www.amo-inc.com.
Forward-Looking Statements
This press release contains forward-looking statements about AMO,
including statements relating to expected shipment dates and
availability and expected impact on financial results and guidance. All
forward-looking statements in this press release are based on estimates
and assumptions and represent AMO's judgment
only as of the date of this press release. Actual results may differ
from current expectations based on a number of factors including but not
limited to market developments, clinical experience, unexpected delays
in manufacturing, and unexpected regulatory, quality or supply chain
issues. Therefore, the reader is cautioned not to rely on these
forward-looking statements. AMO disclaims any intent or obligation to
update these forward-looking statements. Additional information
concerning these and other risk factors may be found in previous press
releases issued by AMO and AMO's public periodic filings with the
Securities and Exchange Commission, including the discussion under the
heading "Risk Factors" in AMO's 2006 Form 10-K filed in March 2007 and
first quarter Form 10-Q. Copies of press releases and additional
information about AMO are available at www.amo-inc.com.
Advanced Medical Optics, Inc.
Investors:
Sheree Aronson,
714-247-8290
sheree.aronson@amo-inc.com
or
Mark
Levin, 714-247-8465
mark.levin@amo-inc.com
or
Media:
Steve
Chesterman, 714-247-8711
steve.chesterman@amo-inc.com
bourse
